CDK14 (cyclin-dependent kinase 14) is a serine/threonine kinase that functions as a cell-cycle regulator primarily through modulation of Wnt/β-catenin signaling. During G2/M phase, CDK14 phosphorylates LRP6 at Ser-1490, activating canonical Wnt signaling and promoting β-catenin stabilization 1. CDK14 expression is regulated by IGF2BP2-mediated mRNA stabilization 1 and transcriptional upregulation via the P300/SP1 complex in castrate-resistant prostate cancer 2. Clinically, CDK14 overexpression correlates with poor prognosis across multiple cancer types. In non-small cell lung cancer, elevated CDK14 expression predicts reduced 5-year overall survival and correlates with proliferation markers 3. CDK14 promotes triple-negative breast cancer progression by enhancing mammary stem cell activity; CDK14 inhibition via FMF-04-159-2 suppresses tumor progression and metastasis 4. In glioblastoma, IRX3 transcriptionally activates CDK14, which stabilizes β-catenin through LRP6-mediated mechanisms, promoting tumor growth 5. Beyond oncology, CDK14 reduction mitigates Parkinson's disease pathology by decreasing α-synuclein accumulation and protecting against neurodegeneration 6. CDK14 also regulates osteogenic differentiation through Wnt/β-catenin signaling, with reduced expression in postmenopausal osteoporosis 1. These findings establish CDK14 as a multi-functional kinase with substantial therapeutic potential across cancer and neurodegenerative diseases.